Download MendeleyNSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma.
Hu, B., Edwards, J., Modi, H., Gamez, J., Echeagaray, O.E., Hess, K., Ren, Y., Anderson, D., Larrayoz, M., Zhu, J., Johnson, S.A., Deb, G., Jankeel, D., Janardhanan, P., Leisten, J., Peng, S., Christoforou, A., Stong, N., Fontanillo, C., Bjorklund, C.C., Hagner, P.R., Gandhi, A.K., Martinez-Climent, J.A., Narla, R.K., Lopez-Girona, A., Rolfe, M., Bence, N., Mortensen, D.S., Groocock, L.(2026) Blood
- PubMed: 42371798 Search on PubMed
- DOI: https://doi.org/10.1182/blood.2025031998
- Primary Citation Related Structures:
9Y60, 9Y61 - PubMed Abstract:
The t(4;14) chromosomal translocation drives overexpression of the histone methyltransferase NSD2 and defines a high-risk segment of multiple myeloma (MM) patients. Herein, we report the discovery of NSD2-LDD, a cereblon-recruiting and PWWP1-mediated ligand directed degrader (LDD) that selectively and potently eliminates full length and PWWP1 domain containing NSD2 protein isoforms. NSD2-LDD treatment induces global loss of H3K36me2 leading to promoter-proximal spreading of H3K27me3 and re-wiring of cis-regulatory interactions that reverse t(4;14) transcriptional programs. These effects suppress MM disease-associated phenotypes including stromal adhesion, three-dimensional colony growth and paracrine signaling. By integrating patient single cell profiles with model 3D epigenomic and spatial transcriptomics, we delineate t(4;14) disease state together with the tumor-intrinsic reprogramming and resultant remodeling of the bone marrow microenvironment upon NSD2 degradation. In cell line derived xenografts and genetically engineered mouse models of t(4;14), NSD2-LDD extends median survival accompanied by tumoral H3K36me2 loss and niche re-modelling. Although the NSD2-LDD response is restricted to PWWP1-containining models, collectively this work validates NSD2 as a tractable dependency and supports clinical development of NSD2 degradation as a novel, targeted therapeutic strategy in high-risk MM.
- Bristol Myers Squibb, San Diego, California, United States.
Organizational Affiliation:
